

Role of Autophagy in Brain Sculpture: Physiological and Pathological Implications

Annalisa Nobili, Virve Cavallucci, and Marcello D'Amelio

Abstract The brain has the ability to change during the life rearranging itself by the elimination and the formation of new connections between neurons. This dynamic capacity is known as brain plasticity or neuroplasticity, and is associated with functional changes involving functional recovery after brain damage, learning, memory, and addiction. It is well defined that protein synthesis is required for neuroplasticity and the establishment of long-term memories, but protein degradation plays also a crucial role in neuronal physiology and pathology. Ubiquitin-proteasome system, which degrades short-lived proteins, is important in synaptic plasticity, learning and memory, as well as lysosome system, which involves endocytosis to degrade proteins, plays a role in synaptic plasticity regulating receptor trafficking. The third major degradation pathway is the autophagy which degrades long-lived cytoplasmic proteins or damaged organelles to maintain normal cell homeostasis. Recent evidence suggests the involvement of autophagy in synaptic plasticity, in addition to its crucial role in the quality control of proteins and organelles in neurons. Thus an impairment of the autophagic machinery is closely connected with the alteration of neuronal function and neuron ability to respond to damage. A clear understanding of neuronal autophagy in brain physiology and pathology could help to develop new pharmaceutical approaches for the treatment of neurological disorders. The current Chapter will focus on the key role of autophagy in the development and function of the central nervous system (CNS), and on the emerging evidence of autophagy deregulation in neurodegenerative disease and acute brain damage.

A. Nobili • M. D'Amelio (✉)

Department of Medicine, University Campus-Biomedico, Via Alvaro del Portillo, 21, Rome, Italy

Department of Experimental Neurosciences, IRCCS S. Lucia Foundation, Rome, Italy

e-mail: m.damelio@unicampus.it

V. Cavallucci

Department of Experimental Neurosciences, IRCCS S. Lucia Foundation, Via del Fosso di Fiorano, 64, Rome, Italy

Abbreviations

3-MA	3-methyladenine
AD	Alzheimer's Disease
Akt (PKB)	Protein kinase B
Ambra1	Autophagy/Beclin-1 Regulator 1
AMPA	α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor
APP	Amyloid precursor protein
ASD	Autism spectrum disorders
Atg	Autophagy-related
ATP	Adenosine triphosphate
AVs	Autophagic vacuoles
A β	β -amyloid peptide
Bcl-2	B-cell lymphoma 2
Bcl-XL	B-cell lymphoma-extra large
Bif-1	BAX-interacting factor-1
Bim	B-cell lymphoma 2 interacting mediator of cell death
CCI	Controlled cortical impact injury
Class III PI3K	Class III phosphatidylinositol 3-kinase
CMA	Chaperone-mediated autophagy
CNS	Central nervous system
COMT	Catechol-o-methyltransferase
Deptor	DEP domain containing MTOR-interacting protein
ER	Endoplasmic reticulum
FAD	Familial AD
Fbxo7	F-box protein 7
FIP200	FAK Family Kinase-Interacting Protein of 200 kDa
FPI	Fluid percussion injury
GABA _A	γ -aminobutyric acid
GCEE	γ -glutamylcysteinyl ethyl ester
H/I	Hypoxia/ischemia
HCb	Hemicerebellectomy
HD	Huntington's disease
HDAC6	Histone deacetylase 6
Htt	Huntingtin
i.c.v.	Intracerebroventricular
IO	Inferior olive
IRGM	Immune-related GTPase M
KO	Knockout
LAMP	Lysosome-associated membrane protein type
LC3	Microtubule-associated protein 1 light chain 3
LRRK2	Leucine-rich repeat kinase 2
LTD	Long-term depression
LTP	Long-term potentiation
MAO-B	Monoamine oxidase B
Mfn1	Mitofusin 1

MPP+	1-methyl-4-phenylpyridinium
mTOR	Mammalian target of rapamycin
mTORC1	mTOR complex 1
NBR1	Neighbor Of BRCA1 Gene 1
Ndp52	Nuclear dot protein 52 kDa
NGF	Nerve growth factor
NMDAR	N-methyl-D-aspartate receptor
NPCs	Neural progenitor cells
NSF	N-ethylmaleimide-sensitive factor
p62/SQSTM1	Sequestosome 1
PD	Parkinson's Disease
PE	Phosphatidylethanolamine
PI3K	Phosphatidylinositol 3-kinase
PI3P	Phosphatidylinositol 3-phosphate
PINK1	PTEN-induced putative kinase 1
pMCAO	Permanent middle cerebral artery occlusion
Pn	Pontine nuclei
polyQ	Polyglutamine
PP1	Protein phosphatase 1
PRAS40	Proline-rich Akt substrate of 40 kDa
PSD95	Postsynaptic density protein 95
PSEN	Presenilin
PTEN	Phosphatase and tensin homolog
Raptor	Regulatory-associated protein of mTOR
Rubicon	RUN and cysteine rich domain containing beclin 1 interacting protein
SCI	Spinal cord injury
SVZ	Subventricular zone
TBI	Traumatic brain injury
tMCAO	Transient middle cerebral artery occlusion
TrkA	Tropomyosin receptor kinase A
Tsc2	Tuberous sclerosis proteins
ULK1	UNC-51-like kinase 1
UVRAG	UV Radiation Resistance-Associated Gene
VDAC1	Voltage-dependent anion channel 1
VMP1	Vacuole Membrane Protein 1
WIPI-1	WD-repeat protein Interacting with PhosphoInositides-1

1 Introduction

Autophagy is a catabolic mechanism that mediates degradation and recycling of cellular constituents, delivering portion of cytoplasm to the lysosomes for degradation. Autophagy is considered to be important to maintain cellular homeostasis, especially under nutrient deprivation or stress conditions, and to guarantee proteins quality control and organelles turnover. Furthermore, autophagy has been


implicated in various cellular processes, such as development, differentiation, ageing and immunity [77, 101, 102].

Autophagy is highly conserved from yeast to mammals and it can be classified in three principal types: microautophagy, chaperone-mediated autophagy (CMA) and macroautophagy [115]. Microautophagy leads to degradation of sequestered portions of cytosol by direct invagination of lysosome membrane [99]. CMA delivers cytosolic protein containing a KFERQ-like motif to the lysosomal lumen via chaperone Hsc70 and LAMP-2A complex [66]. Macroautophagy (hereafter referred to as autophagy) is the well-characterised form of autophagy that leads to the formation of a double-membraned vacuole, the autophagosome, containing cytoplasmic material, such as macromolecules and organelles. Autophagy requires several steps: induction and nucleation of phagophore (the isolation membrane), elongation of phagophore to constitute the autophagosome, maturation of autophagosome into amphisome/autolysosome by fusion with endosome/lysosome and, finally, degradation of membrane contents (Fig. 1). Autophagy is constitutively activated at a basal level to maintain cellular homeostasis but it can also be induced by several input signals, such as nutrient deprivation, change of intracellular levels of Ca^{2+} , ATP and cAMP, hormones, protein accumulation and damaged organelles [136]. The main regulator of autophagy is mTOR (mammalian target of rapamycin) complex 1 (mTORC1), a polyprotein complex that contains mTOR, Raptor, mLST8/GBL, Deptor and PRAS40 [22]; however the autophagy is also regulated by mTOR-independent pathways even though the effectors involved in the autophagosome biogenesis are not clear [136].

More than 30 autophagy-related (Atg) proteins have been identified and characterized in yeast [60, 61] and conserved in mammals, where additional Atg proteins have been identified. However, less than half, the “core Atg proteins” [110, 166], are



Fig. 1 Schematic representation of mammalian autophagy pathway. Following inhibition of mTOR, ULK complex, composed of ULK1, Atg13, FIP200 and Atg101, is activated and starts the autophagosome nucleation. ULK1 also phosphorylates Ambra1, leading to the activation of Beclin1, a component of CIII PI3K complex (or Beclin1 complex), which consists of PI3K or hVps34, Beclin1 and p150. In this step, VMP1 recruits Beclin1 to the phagophore where the complex is required for generating a pool of phosphatidylinositol 3-phosphate (PI3P). To expand the autophagosome membrane, Atg12-Atg5-Atg16L complex and LC3 ubiquitin-like conjugation systems are required. The Atg12-Atg5-Atg16L multimeric complex is formed by subsequent steps involving Atg7 and Atg10 and is also required for the efficient function of LC3. The second system mediates the conjugation of LC3 to phosphatidylethanolamine (PE). LC3 is processed by Atg4, forming the cytosolic LC3 I. Atg7 binds LC3 I and transfers it to Atg3, which catalyses the conjugation to the lipid PE and the conversion of LC3 I in LC3 II. The complete autophagosome fuses with the lysosome and cargo molecules engulfed by autophagosomes are degraded by lysosomal hydrolases and recycled back to the cytoplasm. The specificity of cargo degradation is mediated by selective adaptor proteins, such as p62 that binds ubiquitinated residues of the target proteins or organelles. The steps known to be affected in neurodegenerative diseases and the action of drugs modulating autophagy are indicated. *AD* Alzheimer disease, *HD* Huntington disease, *PD* Parkinson disease. Regulators of autophagy are also indicated. 3-MA, 3-methyladenine



involved in autophagosome formation. These proteins can be subdivided in three functional groups: (1) two kinase complex, ULK complex (consisting of ULK1, Atg13, FIP200 and Atg101) and the class III phosphatidylinositol 3-kinase (CIII PI3K) complex (or Beclin1 complex, comprising PI3K or hVps34, Beclin1 and p150); (2) two ubiquitin-like protein conjugation systems, ATG16L1 complex (Atg12-Atg5-Atg16L) and LC3; (3) two transmembrane proteins, Atg9 (and associated proteins involved in its movement such as WIPI-1) and VMP1.

The activity of ULK complex is important in the induction step of autophagy and is negatively regulated by mTORC1. After autophagy induction, mTORC1 is inactivated, leading to dephosphorylation of ULK1 and Atg13. This event causes the activation of these proteins and the consequent phosphorylation of FIP200 by ULK1. Recently it has been identified a novel ULK complex interactor, Atg101, important for both the stability of Atg13 and basal phosphorylation of Atg13 and ULK1 [48, 98].

Beclin1-CIII PI3K complex is required for the isolation membrane nucleation, generating a pool of phosphatidylinositol 3-phosphate (PI3P), which acts as platform for other Atg proteins recruitment. Beclin1 interacts with several proteins, which are able to modulate the complex activity: Atg14L, UVRAG, Ambra1, and Bif-1 enhance Beclin1 complex activity; the transmembrane protein VMP1 is crucial for the nucleation step, recruiting Beclin1 (and other components of the Beclin1 complex) to the phagophore; whereas Rubicon, the anti-apoptotic proteins Bcl-2 and Bcl-XL and the pro-apoptotic protein Bim negatively regulate autophagy [136].

Following the autophagy induction, ULK1 phosphorylates Ambra1, leading to the activation of Beclin1 and the translocation of the Beclin1-CIII PI3K complex from the microtubule network to the endoplasmic reticulum (ER), which is considered the main membrane source for the biogenesis of phagophore [1, 28, 44]. The fundamental contribution to the biogenesis and elongation of the phagophore from other organelles membrane is mediated by Atg9 [169].

The elongation of the phagophore requires two ubiquitin-like protein conjugation systems. Firstly, Atg5 and Atg12 are conjugated by the ubiquitin-activating E1-like enzyme Atg7. In particular, Atg7 activates Atg12, which is transferred to Atg10, an E2-like enzyme, and then covalently linked with Atg5 ([105, 148]). The Atg12-Atg5 heterodimer binds Atg16L forming a large multimeric complex required for elongation of phagophore [103] and for the efficient function of LC3. The second system mediates the conjugation of LC3 to phosphatidylethanolamine (PE) [41, 103]. LC3 is processed by the protease Atg4, forming the cytosolic LC3 I. Atg7 binds LC3 I and transferred it to Atg3 (E2-like), which catalyses the conjugation to the lipid PE and the conversion of LC3 I in LC3 II. During the expansion of autophagosome, LC3 II is attached both to the inner and outer membrane of this structure. However, until the fusion with the lysosome LC3 II is removed from the outer membrane, while the one in the inner membrane is degraded with the autophagosome cargo [52, 59].

Autophagy has been originally identified as a non-selective process, but recent evidence underlines the importance of selective mechanism, specially involved in the quality control of proteins and organelles. Several post-translational modifica-

tions have been implicated in the regulation of autophagy, one of which is the ubiquitination. The residues of ubiquitin facilitate the recruitment of autophagic receptors and selective adaptor proteins, such as p62 (also called SQSTM1), NBR1, HDAC6, Nix, Ndp52, which tether the targeted substrate to core of Atg proteins, such LC3 [139].

The autophagy mechanism has been analyzed in several tissues and although it occurs in all cell types and involves the same protein complexes, recent studies suggest that this mechanism is tissue-specific regulated. In particular, autophagy plays a crucial role in the brain, in which it is involved as well as in stress response, in quality control of proteins and organelles, even in specific function, such as neurodevelopment, differentiation, learning and memory.

In this Chapter we will discuss the physiological roles of autophagy in neurons and the pathological implications occurring when this process is dysregulated.

2 Neuronal Autophagy

Neurons are highly specialized cells, composed by specific compartments including neurites (axons and dendrites), synapses and soma, in which the synthesis, transport and degradation processes are finely regulated. Moreover, mature neurons are post-mitotic cells, which require an efficient protein quality control system to avoid accumulation of misfolded or aggregated proteins and damaged organelles that cannot be diluted through cell division. Autophagy is of particular importance in the synaptic compartments, characterized by high-energy demand and where a fine control of proteins and organelles turnover is necessary to ensure the activity.

Compared to other organs (such as heart, liver, pancreas, kidney or muscle), in basal condition the brain shows higher level of LC3 and a low number of autophagosomes [112], which do not increase even under nutrient deprivation [106]. Several studies demonstrated that the low presence of autophagic vesicles, analyzed as a low amount of LC3 II then LC3 I, depends on the fast kinetics of vesicles formation and degradation, that reflects the high efficiency of autophagosome turnover [8, 107].

3 The Role of Autophagy in Neurodevelopment and Neurogenesis

The importance of autophagy in development has long been suggested by several studies in which autophagic structures were analyzed during embryogenesis [20, 83] and by studying mutant mice for several *Atg* genes, which have different role in the regulation of development. In fact, mice lacking *Atg3*, *Atg5*, *Atg7*, *Atg9* and *Atg16L1* complete the embryonic development, but die shortly after birth, suggesting that the proteins encoded by these genes are not essential for embryogenesis but have a crucial role in the regulation of perinatal starvation [64, 68, 131, 132, 145]. Instead, Beclin1, Ambra1 or FIP200 deficient mice are embryonic lethal at the

stage E7.5, E10–E14 and E13.5–E16, respectively [35, 37, 174]. The differences among *Atg* genes are not well understood. It seems possible that the role of Beclin1 and FIP200, which interact with several factors, may be related to other function; alternatively, the different lethality may depend on the step in which each factor is involved [104]. In the latter case, *Atg9* constitutes an exception because it acts in early phase of autophagy process but its loss causes a less severe phenotype [146].

The short survival time after birth of *Atg* knockout (KO) mice prevents the study of the *Atg* proteins role, whereas the generation of conditional KO mice allowed to understand their function in specific tissues. Brain-specific deletion of *Atg5* and *Atg7* suggests that these proteins are involved in motor function and that their deficiency results in the development of progressive motor and behavioural deficits. The histological analysis of *Atg5* conditional KO mice shows partial loss of Purkinje cells and neuronal inclusion bodies accumulation. Aggregates of ubiquitinated proteins, which accumulate in a time-dependent manner, are also detected starting at embryonic day E15.5. It has been proposed that basal autophagy in Purkinje neurons is necessary to ensure the correct protein turnover, avoiding aggregates formation [42]. *Atg5* KO embryos also display defects in apoptotic corpse engulfment in photoreceptor and ganglion cell layers of the retina at E18.5 [123]. A recent work has also proposed that *Atg5* plays a central role in developing embryonic cortex to ensure the formation of correct multiple layers architecture. By silencing *Atg5* expression in cortical neural progenitor cells (NPCs), it has been observed that the loss of *Atg5* function leads to unbalanced cortical NPCs differentiation and proliferation and causes the abnormal morphology of cortical neurons. *Atg5* exerts its function in strictly cooperation with β -Catenin and both are required to regulate cortical NPCs differentiation and proliferation [87].

Studies performed on *Atg7* conditional KO mice show that the loss of this protein leads to axonal swellings, with accumulation of aberrant membrane structures and progressive dystrophy and degeneration of the axon terminals in Purkinje cells. Interestingly, these events occur much earlier than the neuronal death, suggesting that basal autophagy is required to regulate membrane homeostasis in the axonal terminals in addition to protein quality control [65].

ULK1 protein regulates axon outgrowth in cerebellum granule neurons and it has been demonstrated that ULK1 is expressed in different neuron population during development and is particular abundant in developing cerebellar granular cells. The inactivation of ULK1 by retroviral injection of its dominant negative form demonstrates that this kinase has a pivotal role in neurite extension/parallel fiber formation [151]. Recent studies also suggest that ULK1 regulates endocytotic trafficking of growth factors, that are necessary during polarized axon elongation. However is not well understood whether ULK1 acts influencing the autophagy mechanism or has a different function through the interaction with several proteins, for example in NGF-TrkA endocytosis [152, 180].

Another example of the importance of autophagy during neurodevelopment comes from the studies conducted on Ambra1 protein. Ambra1 is strongly expressed in developing neuronal tissue starting at the embryonic day E8.5, where is detected in neuroepithelium. Subsequently, a massive expression is observable in the ventral

part of the spinal cord, in the encephalic vesicles, in the neural retina, in the limbs and in the dorsal root ganglia (E11.5); at later stages, *Ambra1* is expressed in the entire developing nervous system; finally, in postnatal brain *Ambra1* is particularly abundant in the cortex, hippocampus and striatum. *Ambra1*-deficient mice display defects in neural tube closure, as well as increased cell proliferation and cell death, that cause exencephaly and/or spina bifida phenotypes [35]. Therefore, *Ambra1* appears to be involved in cell proliferation and survival during neurodevelopment, perhaps controlling the degradation of key development regulators, as demonstrated by the increase of ubiquitinated proteins in *Ambra1*-deficient mice, or directly regulating cell proliferation.

A central role for autophagy has recently been proposed also in adult neurogenesis. *Ambra1* and *Beclin1* are highly expressed in adult subventricular zone (SVZ) of the lateral ventricles, an area where new neurons are generated and then migrate through the rostral migratory stream to the olfactory bulb to become interneurons [100]. It has been demonstrated that autophagy is involved in two different mechanisms in SVZ: on the one hand it sustains the pool of stem cell, on the other hand it enhances the survival of neuronal precursors. In fact, *Beclin1* heterozygous mice show a significant decrease in cell division and an increase in the number of apoptotic cells in SVZ compared to wild-type [171].

Recent evidences support the idea that autophagy plays a fundamental role also in dendritic spine pruning during postnatal life. It has been reported an increase in spine density with reduced developmental spine pruning in layer V pyramidal neurons in postmortem temporal lobe of patients with autism spectrum disorders (ASD). These spine defects correlate with mTOR hyperactivation and autophagy impairment. In fact, Tang and colleagues, using a mTOR constitutively activated mouse model (*Tsc2^{+/-}* mouse, with mutated *Tsc2*, a protein that indirectly inhibit mTOR) observed a postnatal spine pruning defects, blockage of autophagy and ASD-like behaviours. Interestingly, rapamycin is able to revert these phenotypes in *Tsc2^{+/-}* mice but not in *Tsc2^{+/-}; Atg7* conditional KO double mutants, suggesting that autophagy is required for the correct remodelling of dendritic and spine architecture [147].

4 The Synaptic Role of Autophagy

Recent evidences have suggested that autophagy plays an essential role in synaptic plasticity, influencing both pre- and post-synaptic compartments by altering the efficacy of neurotransmitter release or by modifying the post-synaptic density composition (Fig. 2). There are two main forms of synaptic plasticity: long-term potentiation (LTP), where occurs a persistent increase of synaptic efficacies in response to a high-frequency stimulation, and long-term depression (LTD), characterized by a lasting decrease in synaptic effectiveness that follows a pattern of low-frequency stimulation [4, 7]. Both LTP and LTD are considered cellular correlates of learning and memory and for this reason the study of these processes is so intriguing. One of the main receptors involved in synaptic transmission is the




Fig. 2 Representation of autophagy role in pre- and post-synaptic compartment. In the pre-synaptic terminal autophagy alters the efficacy of neurotransmitter release, leading to selective degradation of neurotransmitter-containing vesicles. In the post-synaptic terminal autophagy regulates the degradation of AMPA receptor (AMPA) after chemical induction of long-term depression (LTD). LTD leads to activation of the calcium ion-permeable NMDA receptor (NMDAR). A series of downstream intermediate signaling steps, including activation of protein phosphatases, cause AMPAR endocytosis and induction of LTD. Endosome vesicles containing AMPAR fuse with autophagosomes, forming amphisomes, that finally fuse with lysosomes leading degradation of the AMPAR

α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA), a class of ionotropic glutamate receptors that mediates the excitatory neurotransmission response. The synaptic transmission can be modulated by modifying the exposure of AMPARs in post-synaptic density [144] and by altering the trafficking of AMPARs into and out of synapses [88, 90]. Increased exposure of AMPARs causes a strengthening of synaptic transmission and generally LTP, whereas the removal of AMPARs results in LTD [141, 144]. AMPARs are heterotetrameric complexes, composed of various combination of four subunits (GluA1-4) [47]. In the adult hippocampus GluA subunits are assembled preferably in two major subtypes, GluA1-2, which represent approximately 80% of synaptic receptors, and GluA2-4, which represent the remaining 20% [84, 165]. Recent evidences suggest that AMPARs subunit composition and their interactors on synaptic membrane are able to regulate the trafficking and the targeting of AMPARs to synaptic sites [19, 27, 31, 43, 56, 113, 116, 117, 143, 144]. Moreover, several studies proposed that both GluA1 and GluA2 subunits have a central role in LTD [18, 73, 75, 153, 181]. Upon N-methyl-D-aspartate receptor (NMDAR)-dependent chemical LTD induction, the increase of intracellular Ca^{2+} level leads to the activation of several phosphatases, including PTEN, calcineurin and PP1, that beyond other functions are committed to dephosphorylate GluA1 at Ser 845 residue, promoting its internalization [72], and PSD95 at the Ser295, which is responsible to the recruitment of GluA1 subunit to post-synaptic surface and to the stabilization of the synaptic structure [58]. The GluA2 subunit is stabilized at the synapses by the interaction with NSF (N-ethylmaleimide-sensitive factor), an ATPase that is involved in membrane fusion events [56, 74]. During LTD, it is possible that NSF dissociates from GluA2 and that AP2 binds an overlapping region of GluA2, leading to clathrin-dependent receptor internalization [74, 91]. Internalized AMPARs can be recycled back to the synapses, pooled in the endosomes as a reserve [86, 114] or targeted to lysosome for degradation [33, 75]. Recently it has been proposed that autophagy is responsible for the regulation of neuronal activity, leading to the degradation of AMPARs contained in endocytic vesicle. In fact, after chemical LTD induction the number of autophagosome in dendritic shaft and spines of pyramidal neurons increases, together with a reduction of GluA1 subunits [140]. Degradation of AMPARs, and the consequent LTD stabilization, is partially recovered by application of Okadaic acid and dipotassium bisperoxo (5-hydroxypyridine-2-carboxyl) oxovanadate V, which are inhibitors of PP1 and PTEN, respectively. Both PP1 and PTEN regulate the phosphorylation and the activity of Akt and for this reason it has been suggested that chemical LTD leads to autophagy activation by inhibition of PI3K-Akt-mTOR pathway. Moreover, the inhibition of PI3K by wortmannin and the silencing of Atg7 by lentiviral shRNA infection determine a complete block of LTD-induced autophagy or a partial recovery of GluA1 levels, respectively. It is possible that the increase of the number of autophagosomes, observed in dendritic shafts and spines during LTD, increases the probability of fusion between autophagosomes and endosomes containing GluA subunits to form amphisomes, determining lysosomal degradation of cargo and preventing the receptors recycling in the post-synaptic site. Another interesting possibility is that after LTD induction autophagy acts as a selective degradation mechanism. It has been

reported that GABA_A (γ -aminobutyric acid) receptors, but not acetylcholine receptors, are internalized and degraded selectively by autophagy in *C. elegans* neurons [128]. Moreover p62 protein, which is a selective adaptor protein between cargo and autophagosomes, has an important role in LTP and spatial memory [124] and interacts directly with AMPAR subunits influencing their trafficking to synaptic membrane [51]. It is probable that autophagosomes merge with endosomes containing AMPARs by a p62-mediated mechanism.

Other evidences suggest that autophagy has also a pre-synaptic role regulating neurotransmission [46]. Conditional Atg7 KO mice, in which autophagy deficiency is restricted to dopaminergic neurons, show that inhibition of autophagy in pre-synaptic terminal alters pre-synaptic structure and neurotransmission. In particular, the absence of autophagy results in increased size of axon terminal, increased evoked dopamine release and more rapid pre-synaptic reuptake of neurotransmitter. The pre-synaptic role of autophagy is mTOR-regulated. In fact, acute rapamycin treatment induces a transient augment in the number of autolysosomes in synaptic terminals and at the same time reduces the number of neurotransmitter vesicles. This effect is absent in Atg7 conditional KO mice, indicating that the induction of autophagosome formation by rapamycin requires Atg7. It has been suggested that this mechanism is not specific to dopaminergic neurons. Indeed, rapamycin induces autophagosome-like structures also in other neurons, such as glutamatergic, GABAergic and cholinergic [46].

5 Role of Autophagy in the CNS Diseases

Considering the complexity of autophagic pathway and its importance in neuronal function is not surprisingly that neurons are particularly sensitive to autophagy defects with several pathological implications. Acute and chronic neurodegenerative diseases – including stroke, brain trauma, spinal cord injury, Alzheimer's disease, Parkinson's disease, Huntington's disease – are characterized by mitochondria dysfunction and extensive neuronal cell death. Moreover, the characterization of the autophagic molecular machinery has been followed by abundant studies supporting the key role of autophagy alterations in several human disorders including the above cited brain diseases (Fig. 1).

6 Acute Brain Damage

6.1 Ischemic Stroke

Stroke is one of the main causes of mortality and long-term disability worldwide and the majority of cases are ischemic. Ischemic stroke occurs as a result of a transient or permanent reduction in cerebral blood flow, with consequent lack of oxygen and nutrients in ischemic areas leading to neuronal death. Cerebral ischemia results

in severe intracellular energy stress leading to cell death by a combination of necrotic cell death in infarct core and apoptotic cell death in the ischemic penumbra [32]. In this scenario, the cellular defences against the exhaustion of energy and metabolic stress contribute to neuronal survival. Under stress condition, in neuronal cells exists a subtle balance between life and death and the ultimate fate depends on the cross-talk between different cellular pathways. Since autophagy is induced by cellular stress to enhance cell survival, and many of these stresses (including nutrient deprivation and oxidative stress) occur during cerebral ischemia, in the last years numerous studies have been interested in disentangling the role of autophagy in brain ischemia. Although increased autophagy has been reported in different types of cerebral ischemia (including focal, global and hypoxic/ischemic injury), its role in neuronal death remains controversial. In fact, several works demonstrate that autophagy acts as a protective response after ischemic strokes, whereas other studies show that autophagy inhibition can reduce ischemic damage.

It has been shown that hypoxia/ischemia (H/I) induces Beclin1 expression in the hippocampus and cerebral cortex of neonatal rats (postnatal day 7), and that *in vivo* pharmacological activation of autophagy by rapamycin treatment reduces necrotic cell death and brain injury. Moreover, the inhibition of autophagy by 3-methyladenine (3-MA) accelerates the progression towards necrotic cell death [13]. In addition, both hypoxic preconditioning and prophylactic treatment with simvastatin, which have neuroprotective effect when administered before the onset of H/I in neonatal rats, increase Beclin1 expression after H/I and reduce brain damage, suggesting a protective role of autophagy in the neurodegenerative process that follows neonatal hypoxic-ischemic insult.

Conversely, Koike and Colleagues described that autophagy is strongly induced in the hippocampus following H/I in neonatal mice (postnatal day 7), and they suggested its involvement in neuronal death. In fact Atg7-deficiency protects hippocampal pyramidal neurons from cell death and reduces damaged areas after H/I [63]. In agreement with this work, other studies suggest that autophagy can be implicated in ischemia-induced neuronal death. It has been demonstrated that autophagy activity is increased after transient focal cerebral ischemia in neonatal rats (postnatal day 12) mainly in the border of the lesion, and that post-ischemic intracerebroventricular (i.c.v.) injections of autophagy inhibitor 3-MA reduces the lesion volume. The activation of autophagy in the ischemic penumbra, where delayed cell death occurs, and the neuroprotective effect of post-ischemic autophagy inhibition suggest a detrimental effect of autophagy on neuronal survival [121]. In agreement with these studies, permanent focal ischemia induced in the cortex of adult rats by permanent middle cerebral artery occlusion (pMCAO) causes an increase of autophagosomes, autolysosomes and LC3 conversion (from LC3-I to LC3-II) in cortical neurons. A single i.c.v. injection of bafilomycin or 3-MA after the onset of ischemia reduces the infarct volume [164].

In support of protective role of autophagy, it has been demonstrated that IRGM (immune-related GTPase M, IRGM1 in mouse), a protein that can regulate the survival of immune cells through autophagy, is upregulated in the ischemic side in pMCAO mouse model, concomitantly with a strong autophagic response [45].

Notably, autophagy activation following pMCAO is almost completely lost in IRGM1 KO mice with an increase of infarct volume. Moreover, IRGM1-mediated activation of autophagy in the early phase of ischemia (within 24 h after injury) protects neurons from necrotic cell death in the core of lesion but promotes apoptosis in the penumbra [45].

Furthermore, in adult rats transient middle cerebral artery occlusion (tMCAO) activates autophagy, and in particular mitophagy (a process involved in selective removal of mitochondria by autophagy) [79]. In tMCAO rapamycin attenuates infarct volumes and neurological deficits after cerebral ischemia and 3-MA blocks this protective effect. The observation that rapamycin enhances mitophagy and improves mitochondrial function suggests that the selective removal of damaged mitochondria by autophagy can play an important protective role in ischemic brain injury [79].

Zhang and Colleagues [177] used both pMCAO and tMCAO mouse models of ischemia to understand the role of autophagy in the ischemic and reperfusion phases. Interestingly, they observed that in the pMCAO model, the pre-treatment with 3-MA reduces the ischemia-induced infarct, whereas i.c.v. injection of 3-MA at the onset of reperfusion (tMCAO mice) significantly aggravates brain injury, suggesting that autophagy plays detrimental and protective roles in the ischemia and reperfusion phases, respectively.

Although autophagy is generally considered a cell survival mechanism, massive autophagy can also be associated with cell death through excessive self-digestion and degradation of cellular components. Depending on the context and amount, autophagy may then either protect cell from death or induce cell death. In conclusion, the net effect of ischemic injury-induced autophagy remains controversial and might depend on brain region and maturity, on severity of injury, and on timing of therapeutic interventions. In fact, autophagy could have dissimilar effects depending on stroke model and on the different phases of ischemia (early or late), as well as playing different roles in the core of lesion and in the penumbra area.

6.2 Traumatic Brain Injury

Traumatic brain injury (TBI) refers to brain damage caused by an external mechanical force, which can lead to permanent or temporary impairment of cognitive, physical and psychosocial functions [89]. TBI is the leading cause of mortality and disability in the young aged population under 45 years and represents one of the major causes of hospitalization nowadays: ten million hospitalizations and/or deaths annually are attributable to TBI worldwide [70]. TBI is a complex disease process causing structural damage and motor and cognitive dysfunction produced by both primary and secondary mechanisms. Physical trauma results in the primary early mechanical damage of brain tissue (including hematomas, contusions, ischemia, axonal injury and diffuse swelling). Primary injury can initiate secondary

brain damage (from minutes to months after the trauma) including alteration in neurotransmitter release, calcium-mediated damage, mitochondrial dysfunction, oxidative stress, leading to cell death, tissue damage and atrophy [89, 168]. Neuronal death in TBI is widely attributed to the apoptotic process but several studies have also shown an increase of autophagy after TBI.

In light of the heterogeneity of the clinical aspects of TBI, different animal models (principally rodents) have been developed. Among these, fluid percussion injury (FPI), controlled cortical impact injury (CCI), weight drop-impact acceleration injury, and blast injury are widely used [17, 29, 30, 76, 80, 93].

The use of FPI and CCI rat models has allowed to observe that autophagy is persistently activated after TBI [82, 178]. Autophagosomes accumulate early after TBI (1–4 h) and activation of autophagy persists for days (15–32 days). Since oxygen radicals are involved in the pathogenesis of TBI and autophagy can be induced by mitochondrial oxidative stress, Lai and colleagues analyzed the effects of the antioxidant γ -glutamylcysteinyl ethyl ester (GCEE) on autophagy and neurologic outcome in CCI mouse model of TBI [69]. GCEE treatment decreases the oxidative stress in CCI mice and, more interesting, reduces autophagy levels after TBI, with an improvement of cognitive performance in Morris water maze test and a partial reduction of histological damage. These data suggest that oxidative stress is involved in the neuropathology of TBI and can influence autophagy activity after acute brain injury.

In addition to oxidative stress, glutamate excitotoxicity also plays an important role in TBI. Hyperactivation of NMDARs is associated with TBI-induced neuronal death and excitotoxicity has been linked to autophagy. Interestingly, it has been demonstrated that NMDAR subunit GluN2A (and its signalling intermediates PSD-95, Homer and Shank) interacts with Beclin1 in membrane rafts of rat cerebral cortex neurons. FPI-induced TBI, in addition to increase the levels of GluN2A, causes a rapid redistribution of Beclin1 out of membrane rafts and activates autophagy pathway [6]. These data suggest that the release of Beclin1 (or PSD95/Shank/Homer/Beclin1) from the GluN2B multi-protein signalling complex in response to TBI-induced excessive stimulation of GluN2A could be a key event involved in the activation of neuronal autophagy.

Although several studies demonstrated that autophagy is activated in different TBI models, its role as a protective or detrimental process remains unclear. In order to investigate the function of autophagy after TBI, Luo and Colleagues tested the effects of autophagy inhibitors in weight-drop mouse model. They observed that the administration of autophagy inhibitors (3-MA and bafilomycin; single i.c.v. injection before TBI) blocks TBI-induced autophagy, attenuates TBI-induced cell death and brain lesions, and improves TBI-induced motor and learning deficits [85].

In conclusion, TBI causes pathophysiological responses that lead to oxidative stress, glutamate excitotoxicity, cell death, motor and cognitive outcome deficits. In this context, autophagy has been identified as part of the responses leading to cell injury after TBI and different compounds tested as neuroprotective in TBI have been shown to reduce apoptotic neuronal death as well as autophagic activity [25, 81, 161, 158, 176].

6.3 *Spinal Cord Injury*

Spinal cord injury (SCI) is a high-cost neurological disability that can leave the individual with severe life-lasting impairment affecting all organ systems, with strong impact on the patient, the family, health care service, and society. SCI refers to any injury, complete or incomplete, to the spinal cord causing different types of motor, sensory and sphincter dysfunction, as well as dystonia [10]. Extreme sports, high-speed transport, and traumatic accidents in general are linked with a particularly high incidence of SCI, which has an annual incidence of 50 individuals per million population with prevalence in young adults [120, 162].

SCI can be studied in mice and rats models, by means the hemisection of spinal cord at different vertebral levels. It has been observed that SCI causes a fast autophagy activation at the lesion site. Specifically, the upregulation of autophagic markers starts 4 h after the lesion, with a peak at 3 days, and lasts for 21 days [49, 53]. The observed persistent increase of key proteins involved in autophagic pathway in degenerating axons [127] suggests that autophagy might be involved in axonal degeneration following traumatic injury.

However, the role of autophagy in SCI needs to be further investigated in order to understand whether this process contributes to neuronal death or represents a neuroprotective response.

6.4 *Remote Damage*

Acute brain injury is characterized by two events: (1) early primary damage that directly causes cell death and degeneration, and (2) late secondary damage that induces delayed neurodegeneration through other mechanisms that are not limited to the lesion site but can involve remote areas. Remote neurodegeneration is a multifactorial phenomenon that develops days or months after acute damage and strongly affects the clinical outcome in many CNS disorders [156]. Axotomized neurons undergo a series of morphological changes before dying and the severity of remote cell death is associated to several factors, such as the type and extent of the primary lesion, the distance between axonal trauma and the soma, the type of connectivity, and the intrinsic vulnerability of the involved circuits [34].

Remote damage can be studied in animal models by means axotomy and target deprivation in order to analyze the morphological, biochemical, and ultrastructural changes that occur days to months after injury in different brain circuits. The hemi-cerebellectomy (HCb) is a widely used model to study the mechanisms of remote cell death. HCb consists in the ablation of half of the cerebellum, which leads, because of the crossed input–output cerebellar organization, to the damage of all neuronal axons of the contralateral inferior olive (IO) and pontine nuclei (Pn) and to deprivation of nearly all cerebellar input of the contralateral cerebral cortex [108, 156]. Recently, we analyzed autophagy function and kinetics during apoptotic cell

death in HCB-induced remote damage [155]. We demonstrated that acute brain lesions activate autophagy in axotomized neurons and that this event is subsequent to cytochrome c release from the mitochondria. Importantly, we showed that autophagy stimulation by the mTOR inhibitor rapamycin reduces neuronal death and improves functional recovery after HCB. By contrast, autophagy-impaired *Beclin1* heterozygous mice undergo a greater degeneration of axotomized neurons. These data suggest that, in remote damage induced by HCB, activation of autophagy in axotomized neurons acts as a reactive response that protects neurons by engulfing damaged mitochondria and neutralizing pro-apoptotic factors that can cause cell death [155]. In agreement with this hypothesis we recently observed that HCB alters mitochondrial dynamics (fusion/fission) balance in axotomized neurons and that the neuroprotective effect of rapamycin seems to be the result of a dual role: on one hand the stimulation of autophagy leads to damaged mitochondria removal and on the other hand the enhancement of mitochondria fission allows their elimination by mitophagy [14].

Conversely, in remote damage induced by corticovascular focal lesion autophagy activation seems to have detrimental effects. Focal cerebral infarction can be induced by distal MCAO and can cause secondary degeneration of thalamus and delay functional recovery. After the lesion, autophagy is activated in the ipsilateral thalamus and its inhibition (by using *Beclin1* KO and 3-MA treatment) results in a decrease of neuronal loss, gliosis and apoptosis [167]. These data suggest that the inhibition of autophagy can attenuate the secondary thalamic damage after focal cerebral infarction.

Although it is not possible to draw clear and general conclusions on the role of autophagy in remote damage, because of the different responses depending on the type of primary lesion, several lines of evidence implicate autophagy as a pathophysiological mechanism of remote damage and suggest that drugs targeting this process could be useful to reduce remote neurodegeneration.

7 Neurodegenerative Diseases

7.1 Alzheimer's Disease

Alzheimer's Disease (AD) is a progressive and irreversible age-related neurodegenerative disorder leading to cognitive, memory and behavioural impairments and represents the most cause of dementia worldwide. The main histopathological features of AD brains are the presence of extracellular senile plaques principally formed by the β -amyloid peptide ($A\beta$), intracellular neurofibrillary tangles constituted by hyperphosphorylated aggregates of the microtubule-associated protein tau, altered neuronal connectivity and massive neuronal loss principally in the hippocampus and cerebral cortex [15]. AD is primarily a sporadic pathology, with age as main risk factor; however, autosomal dominant familial forms are known (familial AD,

FAD). The first mutation causing FAD has been recognized in the amyloid precursor protein (APP) encoding-gene on chromosome 21 [40, 149]. Subsequently AD-related mutations in the presenilin 1 (*PSEN1*, on chromosome 14) and presenilin 2 (*PSEN2*, on chromosome 1) genes have also been identified [78, 142]. Pathogenic mutations in these three genes account for the majority of familial cases of early-onset AD and several mutations in the *APP*, *PSEN1* and *PSEN2* genes have been described worldwide. To note, the mutations causing early-onset autosomal dominant AD affect the metabolism and the stability of A β peptide, a proteolytic product of APP processing, that plays a crucial role in AD pathogenesis [138].

A β is generated in endo-lysosomal pathway and is present in autophagosomes and in lysosomes. The evidence that autophagic vacuoles (AVs) contain APP and are enriched in β - and γ -secretase activity (responsible for amyloidogenic APP processing with production of A β) implicates that AVs are active compartments for A β generation [172, 173] and a major source of intracellular A β in AD brain [172]. The evidence that autophagy is induced in AD comes out from the study of vulnerable neuronal populations before the extracellular deposition of A β in PS1/APP transgenic mouse model of AD. Moreover, dystrophic neurites strongly accumulate autophagosomes and other immature AVs [172], involving an impairment in the normal maturation of AVs to lysosomes and suggesting that a change in the autophagy rate or abnormal AVs accumulation in affected AD neurons can contribute to A β deposition. However, more recently it has been demonstrated that autophagy stimulation by rapamycin does not alter APP metabolism and A β secretion, suggesting that autophagy is not directly involved in APP metabolism [9]. Rather, it seems likely that the accumulation of APP C-terminal fragments (observable when lysosomal flux is impaired) is caused by a defect of endosome-derived APP or APP C-terminal fragments clearance rather than to an increase of newly generated autophagosomes. In addition to A β pathology involvement, autophagy-lysosomal system can also degrade both soluble tau and tau aggregates and inhibition of this mechanism leads to enhanced tau aggregation and cytotoxicity [160]. The involvement of autophagy in the pathogenesis of the two hallmarks of AD brain, amyloid plaques and neurofibrillary tangles, is confirmed by the observation that the pharmacological restoring of mTOR signalling with rapamycin rescues cognitive deficits and ameliorates A β and tau pathology by increasing autophagy in the 3xTg-AD mouse model of AD [12].

A role of autophagy in AD pathogenesis is also suggested by the evidence that Beclin1 levels are decreased in affected brain regions of AD patients in early stage of the disease [119]. However, in two different lines of APP transgenic mice (J20 and T41 mouse models of AD) the levels of Beclin1 are not reduced at old age, while Beclin1 deficiency (*Beclin1* heterozygous mice) promotes extracellular and intraneuronal A β deposition in APP transgenic mice. These data suggest that the overproduction of mutant APP and the development of amyloid pathology is not sufficient to reduce Beclin1 expression in mice and that the reduction of Beclin1 observed in AD brains likely occurs upstream of APP pathology [119]. The enhancement of autophagic protein turnover rate and lysosomal cathepsin activities in TgCRND8 mouse model (by genetic deletion of cystatin B, an inhibitor of lyso-

somal cysteine proteases) rescues autophagic-lysosomal pathology and the abnormal accumulation of A β , ubiquitinated proteins and other autophagic substrates. The improvement of lysosomal function in this model reduces intraneuronal levels of A β as well as extracellular amyloid deposition, and prevents learning and memory deficits [170].

In addition to its role in the clearance of A β and tau in AD pathology, autophagy is also involved in the removal of damaged organelles. Mitochondrial abnormalities correlate with dystrophic neurites, dendritic branches loss and dendritic spines pathological alteration present in AD brains [2]. Several line of evidence demonstrate that A β damages mitochondria and the reduction of lysosomal degradative efficiency can limit mitochondrial recycling. The impairment of autophagy in aging cells and the positive correlation between A β content and mitochondrial damage suggest that mitochondrial turnover could progressively decline with age, with consequent increase of oxidative damage, accumulation of dysfunctional mitochondria and finally cell death [16]. The literature about AD and mitophagy is not very abundant but several evidences, including the impairment of mitochondrial fission/fusion events which are involved in mitochondrial elimination by autophagy, imply that an inefficient lysosomal system may compromise the elimination of damaged mitochondria in AD [134, 159].

7.2 *Parkinson's Disease*

Parkinson's Disease (PD) is the second most common neurodegenerative disorder characterized by bradykinesia, resting tremor, rigidity, and postural instability. The movement deficits principally result from the massive and selective degeneration of nigrostriatal dopaminergic neurons with consequent striatal dopamine deficiency. Another pathological feature of PD brains is the abnormal accumulation of fibrillar α -synuclein protein leading to the formation of intracellular insoluble inclusions (Lewy bodies) and degenerating ubiquitin-positive neuronal processes (Lewy neurites) in surviving neurons [36, 109]. Currently there is no convincing therapy to block or slowdown neuronal loss but only symptomatic treatments are available. Indeed, dopaminergic deficit can be temporarily compensated with deep brain stimulation and by treatment with dopamine agonists, dopamine precursor L-dopa, monoamine oxidase B (MAO-B) and catechol-o-methyltransferase (COMT) inhibitors [21]. PD incidence markedly increases with age although a rare young-onset PD occurring before age 40 exists. PD is principally a sporadic disease (90% of cases) but several PD-related genes have been identified in a subset of familial forms of the disorder. Genetic transmission can be autosomal dominant – mutations in the genes encoding for α -synuclein and LRRK2 (leucine-rich repeat kinase) – or autosomal recessive – mutations in the genes encoding for PINK1 (PTEN-induced putative kinase 1), parkin and DJ-1 [109].

Aging, genetic factors, and environmental exposure to pesticides and heavy metals are implicated in PD pathogenesis, and mitochondrial dysfunction and oxi-

ductive stress have long been associated to PD. Mitochondrial quality control ensures the functionality of the mitochondria during cell life and the deterioration of cellular mechanisms involved in mitochondria turnover has been hypothesized to underlie the pathogenesis of several neurodegenerative diseases, in particular PD [150]. Notably, among the genes related to familial forms of PD, there are two genes encoding for proteins involved in mitochondrial quality control. PINK1 is a serine/threonine kinase normally present at very low levels in healthy polarized mitochondria; however, when mitochondria are depolarized, full-length PINK1 accumulates rapidly at damaged organelles, and recruits parkin from the cytosol to the mitochondria. Parkin is an E3 ubiquitin ligase that catalyzes the polyubiquitination of several substrates, including the mitochondrial proteins Mfn1 (mitofusin 1) and VDAC1 (voltage-dependent anion channel 1), and triggers mitochondrial engulfment by autophagosomes and subsequent degradation through mitophagy [38, 39, 96, 111]. Interestingly, another protein linked to recessive juvenile parkinsonism, Fbxo7, is involved in mitochondrial maintenance regulating PINK1/parkin-mediated mitophagy. Fbxo7, in fact, participates in parkin recruitment to damaged mitochondria and Mfn1 ubiquitination [11, 179]. Rare cases of autosomal recessive PD are caused by loss-of-function mutations in the gene encoding for DJ-1, an ubiquitous redox-responsive cytoprotective protein. In addition to antioxidant effects, DJ-1 also regulates autophagy and contributes to the maintenance of mitochondrial function. In fact, the loss of DJ-1, leads to mitochondrial membrane potential reduction, mitochondrial fragmentation, and autophagic markers accumulation [50, 97]. Collectively, these observations implicate the failure of damaged mitochondria removal through mitophagy as a contributing factor in PD pathogenesis.

Aberrant accumulation of α -synuclein, the major protein in Lewy bodies, is associated with PD pathogenesis and mutations in α -synuclein cause early-onset PD. In inducible α -synuclein-overexpressing cell line it has been demonstrated that α -synuclein can be degraded either by ubiquitin/proteasome system and autophagy pathway. In this *in vitro* model, in fact, α -synuclein is presents in structures with the morphological features of autophagic vesicles and stimulation of autophagy by rapamycin increases its clearance [163]. Afterwards, it has been demonstrated that wild-type α -synuclein is internalized and degraded in lysosomes by CMA, and that mutant forms of this protein (both A30P and A53T mutant) bound specific receptors on lysosomes membrane stronger than wild-type but are poorly internalized [24]. Thus, wild-type α -synuclein seems to be efficiently degraded via CMA, whereas the degradation of mutant α -synuclein is impaired. The blockade of CMA then results in a compensatory activation of macroautophagy, which fails to maintain normal rates of protein degradation [24]. Several studies support an involvement of proteasomal, lysosomal and autophagic pathways in PD, although there is no general consensus about the main pathway responsible for α -synuclein degradation. However, it seems that all the three proteolytic pathways are involved in α -synuclein clearance [5, 24, 163]. Numerous studies have suggested a link between LRRK2 (leucine-rich repeat kinase 2), an important genetic contributor to PD, and aberrant autophagy. LRRK2 is associated with late-onset PD displaying variable pathology depending

on the type of mutation [92, 95, 175]. Mutated LRRK2 has been shown to induce or inhibit autophagy depending on specific mutation or cell type [130, 133].

In conclusion, mounting evidence implicates dysfunctional autophagy and mitophagy in PD pathogenesis. Many gene mutations causing familial PD have been identified and many of these alter autophagy. In addition, PD toxins (as MPP+, rotenone, 6-hydroxydopamine, and paraquat) also deregulate autophagy [26], highlighting the importance of this process in PD pathogenesis.

7.3 *Huntington's Disease*

Huntington's disease (HD) is an autosomal dominant inherited neurodegenerative disorder characterized by abnormal repetitive movements called chorea, progressive dementia and psychiatric manifestations. The main pathological alteration in HD brains is the selective neuron loss occurring in the striatum and cortex. The onset of symptoms is typically in the middle-age but the disorder can manifest at any time. HD causes death 15–20 years after the onset of neurological manifestations, and although there are treatments that can help to control choreiform movements, successful therapy to block disease progression does not exist [157]. The mutant protein in HD results from an abnormal expansion of the trinucleotide sequence CAG in the first exon of *huntingtin* gene, resulting in an excessive extension of variable length of the polyglutamine (polyQ) tract at the N-terminus of huntingtin (Htt) protein with a toxic gain of function. The normal allele contains a repeated sequence of 10–35 CAG triplets. The expansion of this CAG repeat over 35 is linked with the development of disease, and the length of polyQ tract is inversely correlated with the age-onset of HD [67, 129]. The production and accumulation of misfolded Htt cause the formation of inclusion bodies in HD brain leading to the selective loss of striatal GABAergic neurons.

Different mechanisms have been suggested to contribute to the pathogenesis of HD, including excitotoxic injury, oxidative stress, mitochondrial dysfunction, and apoptosis. As autophagy is primarily responsible for maintaining normal cellular protein homeostasis in the CNS and HD is a neurodegenerative proteinopathy (as other neurodegenerative disease such as AD and PD), it is not surprising that autophagy has attracted the interest of scholars in the field. Several lines of research have reported autophagy dysfunction in HD and have shown that autophagy modulation could represent a potential therapeutic intervention.

Increased number of AVs has been reported in human HD samples and in different experimental models. Initially it has been observed that Htt abnormally accumulates in punctate cytoplasmic structures resembling endosomal-lysosomal organelles in HD brains [135] and that wild-type and mutant Htt associate with endosomes in human-derived primary fibroblasts [154]. Then, in clonal mouse striatal cell line transiently transfected with human Htt it has been demonstrated that both wild-type and mutant Htt accumulate in the cytoplasm forming vacuoles [57], which incorporate the lysosomal enzyme cathepsin D in proportion to polyQ length and have the

ultrastructural features of autophagosome [55]. Primary striatal neurons from transgenic HD mice (R6/2 mouse model expressing exon one of the human Htt gene carrying a CAG repeat expansion) exposed to neurotoxic concentration of dopamine not only present increased cell death compared to wild-type neurons, but also exhibit lysosome-associated responses with the induction of autophagic granules and electron-dense lysosomes [118].

Mutant Htt can sequester and inactivate mTOR, thus promoting autophagy in HD brain [126] and accumulation of the autophagic markers p62 and LC3 in the striatum of transgenic mouse models of HD [71]. Therefore, several studies suggest that dysfunctional autophagy can be involved in HD pathogenesis. However, the increase of autophagosomes in cellular and mouse model of HD is not accompanied by an increase of autophagic substrates degradation although autophagic flux does not appear to be affected [94]. In fact, in HD cells AVs form with normal or enhanced rates and are effectively eliminated by lysosomes but there is a defect in autophagic cargo recognition with the formation of “empty” autophagosome. As a result, despite an increase in the initiation of autophagy and the formation of AVs, aggregated proteins (including Htt) and damaged mitochondria are not degraded and accumulate in the cytoplasm contributing to toxicity [94].

Many cell types respond to autophagy blockade by upregulating CMA [54] and CMA results increased in cellular and mouse models of HD [62]. Htt has two putative KFERQ-like CMA-targeting motifs; the pentapeptide motif KFERQ is recognized by cytosolic chaperone Hsc70 that targets the substrates to lysosomes, where they are bound by the lysosome-associated membrane protein type 2A (LAMP-2A), which mediates substrate translocation into the lysosomal lumen [23]. Notably, CMA-dependent degradation of Htt fragments is less efficient for polyQ-expanded Htt fragments, perhaps because polyQ expansion in mutant Htt delays the transport across the lysosomal membrane, with consequent accumulation into the cytosol [62, 122]. CMA targets selectively N-terminal fragments of Htt (while full-length polyQ-Htt is primarily targeted by autophagy), and specific targeting of N-terminal polyQ-Htt fragment to the CMA pathway strongly reduces the formation of cytosolic inclusion and improves HD phenotypes in R6/2 mice [3].

As rapamycin treatment reduces aggregate formation and cell death in cells expressing mutant Htt [125], small molecules which enhance autophagy are able to reduce toxicity in HD models [137], and several mTOR-independent autophagy inducers increase the clearance of mutant Htt and reduce its toxicity [136], the manipulation of autophagy and CMA could represent a promising candidate for therapy development.

8 Conclusions

In this Chapter we have described autophagic mechanism and its fundamental role in neuronal function. We have highlighted that autophagy plays a key role in the physiology of the central nervous system, not only as quality control mechanism but

also for brain development and synaptic function. The emerging evidences that autophagy defects are involved in common neurodegenerative diseases and that acute brain injuries are characterized by strong autophagic responses encourage to unravel the role of autophagy in brain diseases and open the possibility of future therapeutic approaches.

References

1. Axe EL, Walker SA, Manifava M, Chandra P, Roderick HL, Habermann A, Griffiths G, Ktistakis NT (2008) Autophagosome formation from membrane compartments enriched in phosphatidylinositol 3-phosphate and dynamically connected to the endoplasmic reticulum. *J Cell Biol* 182:685–701
2. Baloyannis SJ (2009) Dendritic pathology in Alzheimer's disease. *J Neurol Sci* 283:153–157
3. Bauer PO, Goswami A, Wong HK, Okuno M, Kurosawa M, Yamada M, Miyazaki H, Matsumoto G, Kino Y, Nagai Y, Nukina N (2010) Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein. *Nat Biotechnol* 28:256–263
4. Bear MF, Abraham WC (1996) Long-term depression in hippocampus. *Annu Rev Neurosci* 19:437–462
5. Bennett MC, Bishop JF, Leng Y, Chock PB, Chase TN, Mouradian MM (1999) Degradation of α -synuclein by proteasome. *J Biol Chem* 274:33855–33858
6. Bigford GE, Alonso OF, Dietrich D, Keane RW (2009) A novel protein complex in membrane rafts linking the NR2B glutamate receptor and autophagy is disrupted following traumatic brain injury. *J Neurotrauma* 2:703–720
7. Bliss TVP, Collingridge GL (1993) A synaptic model of memory: longterm potentiation in the hippocampus. *Nature* 361:31–39
8. Boland B, Kumar A, Lee S, Platt FM, Wegiel J, Yu WH, Nixon RA (2008) Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease. *J Neurosci* 28:6926–6937
9. Boland B, Smith DA, Mooney D, Jung SS, Walsh DM, Platt FM (2010) Macroautophagy is not directly involved in the metabolism of amyloid precursor protein. *J Biol Chem* 285:37415–37426
10. Bregman BS, Kunkel-Bagden E, Schnell L, Dai HN, Gao D, Schwab ME (1995) Recovery from spinal cord injury mediated by antibodies to neurite growth inhibitors. *Nature* 378:498–501
11. Burchell VS, Nelson DE, Sanchez-Martinez A, Delgado-Camprubi M, Ivatt RM, Pogson JH, Randle SJ, Wray S, Lewis PA, Houlden H, Abramov AY, Hardy J, Wood NW, Whitworth AJ, Laman H, Plun-Favreau H (2013) The Parkinson's disease-linked proteins Fbxo7 and Parkin interact to mediate mitophagy. *Nat Neurosci* 16:1257–1265
12. Caccamo A, Majumder S, Richardson A, Strong R, Oddo S (2010) Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. *J Biol Chem* 285:13107–13120
13. Carloni S, Buonocore G, Balduini W (2008) Protective role of autophagy in neonatal hypoxia-ischemia induced brain injury. *Neurobiol Dis* 32:329–339
14. Cavallucci V, Bisicchia E, Cencioni MT, Ferri A, Latini L, Nobili A, Biamonte F, Nazio F, Fanelli F, Moreno S, Molinari M, Viscomi MT, D'Amelio M (2014) Acute focal brain damage alters mitochondrial dynamics and autophagy in axotomized neurons. *Cell Death Dis* 5:e1545. doi:10.1038/cddis.2014.511
15. Cavallucci V, D'Amelio M, Cecconi F (2012) A β toxicity in Alzheimer's disease. *Mol Neurobiol* 45:366–378

16. Cavallucci V, Ferraina C, D'Amelio M (2013) Key role of mitochondria in Alzheimer's disease synaptic dysfunction. *Curr Pharm Des* 19:6440–6450
17. Cernak I, Savic J, Malicevic Z, Zunic G, Radosevic P, Ivanovic I, Davidovic L (1996) Involvement of the central nervous system in the general response to pulmonary blast injury. *J Trauma* 40:S100–S104
18. Chung HJ, Steinberg JP, Huganir RL, Linden DJ (2003) Requirement of AMPA receptor GluR2 phosphorylation for cerebellar long-term depression. *Science* 300:1751–1755
19. Chung HJ, Xia J, Scannevin RH, Zhang X, Huganir RL (2000) Phosphorylation of the AMPA receptor subunit GluR2 differentially regulates its interaction with PDZ domain-containing proteins. *J Neurosci* 20:7258–7267
20. Clarke PG (1990) Developmental cell death: morphological diversity and multiple mechanisms. *Anat Embryol* 181:195–213
21. Connolly BS, Lang AE (2014) Pharmacological treatment of Parkinson disease: a review. *JAMA* 311:1670–1683
22. Efeyan A, Sabatini DM (2011) mTOR and cancer: many loops in one pathway. *Curr Opin Cell Biol* 22:169–176
23. Cuervo AM (2010) Chaperone-mediated autophagy: selectivity pays off. *Trends Endocrinol Metab* 21:142–150
24. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D (2004) Impaired degradation of mutant α -synuclein by chaperone-mediated autophagy. *Science* 305:1292–1295
25. Cui C, Cui Y, Gao J, Sun L, Wang Y, Wang K, Li R, Tian Y, Song S, Cui J (2014) Neuroprotective effect of ceftriaxone in a rat model of traumatic brain injury. *Neurosci* 35:695–700
26. Dagda RK, Das Banerjee T, Janda E (2013) How Parkinsonian toxins dysregulate the autophagy machinery. *Int J Mol Sci* 14:22163–22189
27. Daw MI, Chittajallu R, Bortolotto ZA, Dev KK, Duprat F, Henley JM, Collingridge GL, Isaac JT (2000) PDZ proteins interacting with C-terminal GluR2/3 are involved in a PKC-dependent regulation of AMPA receptors at hippocampal synapses. *Neuron* 28:873–886
28. Di Bartolomeo S, Corazzari M, Nazio F, Oliverio S, Lisi G, Antonioli M, Pagliarini V, Matteoni S, Fuoco C, Giunta L, D'Amelio M, Nardacci R, Romagnoli A, Piacentini M, Cecconi F, Fimia GM (2010) The dynamic interaction of AMBRA1 with the dynein motor complex regulates mammalian autophagy. *J Cell Biol* 191:155–168
29. Dixon CE, Clifton GL, Lighthall JW, Yaghmai AA, Hayes RL (1991) A controlled cortical impact model of traumatic brain injury in the rat. *J Neurosci Methods* 39:253–262
30. Dixon CE, Lyeth BG, Povlishock JT, Findling RL, Hamm RJ, Marmarou A, Young HF, Hayes RL (1987) A fluid percussion model of experimental brain injury in the rat. *J Neurosurg* 67:110–119
31. Dong H, O'Brien RJ, Fung ET, Lanahan AA, Worley PF, Huganir RL (1997) GRIP: a synaptic PDZ domain-containing protein that interacts with AMPA receptors. *Nature* 386:279–284
32. Donnan GA, Fisher M, Macleod M, Davis SM (2008) Stroke. *Lancet* 371:1612–1623
33. Ehlers MD (2000) Reinsertion or degradation of AMPA receptors determined by activity-dependent endocytic sorting. *Neuron* 28:511–525
34. Faden AI (2002) Neuroprotection and traumatic brain injury: theoretical option or realistic proposition. *Curr Opin Neurol* 15:707–712
35. Fimia GM, Stoykova A, Romagnoli A, Giunta L, Di Bartolomeo S, Nardacci R, Corazzari M, Fuoco C, Ucar A, Schwartz P, Gruss P, Piacentini M, Chowdhury K, Cecconi F (2007) Ambra1 regulates autophagy and development of the nervous system. *Nature* 447:1121–1125
36. Forno LS (1996) Neuropathology of Parkinson's disease. *J Neuropathol Exp Neurol* 55:259–272
37. Gan B, Peng X, Nagy T, Alcaraz A, Gu H, Guan JL (2006) Role of FIP200 in cardiac and liver development and its regulation of TNF α and TSC-mTOR signaling pathways. *J Cell Biol* 175:121–133

38. Geisler S, Holmstrom KM, Skujat D, Fiesel FC, Rothfuss OC, Kahle PJ, Springer W (2010) PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. *Nat Cell Biol* 12:119–131
39. Glauser L, Sonnay S, Stafa K, Moore DJ (2011) Parkin promotes the ubiquitination and degradation of the mitochondrial fusion factor mitofusin 1. *J Neurochem* 118:636–645
40. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, Mantparallel R, Newton P, Rooke K, Roques P, Talbot C, Pericak-Vance M, Roses A, Williamson R, Rossor M, Owenparallel M, Hardy J (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. *Nature* 349:704–706
41. Hanada T, Noda NN, Satomi Y, Ichimura Y, Fujioka Y, Takao T, Inagaki F, Ohsumi Y (2007) The Atg12-Atg5 conjugate has a novel E3-like activity for protein lipidation in autophagy. *J Biol Chem* 282:37298–37302
42. Hara T, Nakamura K, Matsui M, Yamamoto A, Nakahara Y, Suzuki-Migishima R, Yokoyama M, Mishima K, Saito I, Okano H, Mizushima N (2006) Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. *Nature* 441:885–889
43. Hayashi Y, Shi SH, Esteban JA, Piccini A, Poncer JC, Malinow R (2000) Driving AMPA receptors into synapses by LTP and CaMKII: requirement for GluR1 and PDZ domain interaction. *Science* 287:2262–2267
44. Hayashi-Nishino M, Fujita N, Noda T, Yamaguchi A, Yoshimori T, Yamamoto A (2009) A subdomain of the endoplasmic reticulum forms a cradle for autophagosome formation. *Nat Cell Biol* 11:1433–1437
45. He S, Wang C, Dong H, Xia F, Zhou H, Jiang X, Pei C, Ren H, Li H, Li R, Xu H (2012) Immune-related GTPase M (IRGM1) regulates neuronal autophagy in a mouse model of stroke. *Autophagy* 8:1621–1627
46. Hernandez D, Torres CA, Setlik W, Cebrián C, Mosharov EV, Tang G, Cheng HC, Kholodilov N, Yarygina O, Burke RE, Gershon M, Sulzer D (2012) Regulation of presynaptic neurotransmission by macroautophagy. *Neuron* 74:277–284
47. Hollmann M, Heinemann S (1994) Cloned glutamate receptors. *Annu Rev Neurosci* 17:31–108
48. Hosokawa N, Sasaki T, Iemura S, Natsume T, Hara T, Mizushima N (2009) Atg101, a novel mammalian autophagy protein interacting with Atg13. *Autophagy* 5:973–979
49. Hou H, Zhang L, Zhang L, Tang P (2014) Acute spinal cord injury in rats should target activated autophagy. *J Neurosurg Spine* 20:568–577
50. Irrcher I, Aleyasin H, Seifert EL, Hewitt SJ, Chhabra S, Phillips M, Lutz AK, Rousseaux MW, Bevilacqua L, Jahani-Asl A, Callaghan S, MacLaurin JG, Winklhofer KF, Rizzu P, Rippstein P, Kim RH, Chen CX, Fon EA, Slack RS, Harper ME, McBride HM, Mak TW, Park DS (2010) Loss of the Parkinson's disease-linked gene DJ-1 perturbs mitochondrial dynamics. *Hum Mol Genet* 19:3734–3746
51. Jiang J, Parameshwaran K, Seibenhener ML, Kang MG, Suppiramaniam V, Haganir RL, Diaz-Meco MT, Wooten MW (2009) AMPA receptor trafficking and synaptic plasticity require SQSTM1/p62. *Hippocampus* 19:392–406
52. Kabeya Y, Mizushima N, Yamamoto A, Oshitani-Okamoto S, Ohsumi Y, Yoshimori T (2004) LC3, GABARAP and GATE16 localize to autophagosomal membrane depending on form-II formation. *J Cell Sci* 117:2805–2812
53. Kanno H, Ozawa H, Sekiguchi A, Itoi E (2009) Spinal cord injury induces upregulation of Beclin 1 and promotes autophagic cell death. *Neurobiol Dis* 33:143–148
54. Kaushik S, Massey AC, Mizushima N, Cuervo AM (2008) Constitutive activation of chaperone-mediated autophagy in cells with impaired macroautophagy. *Mol Biol Cell* 19:2179–2192
55. Kegel KB, Kim M, Sapp E, McIntyre C, Castaño JG, Aronin N, DiFiglia M (2000) Huntingtin expression stimulates endosomal-lysosomal activity, endosome tubulation, and autophagy. *J Neurosci* 20:7268–7278

56. Kim CH, Chung HJ, Lee HK, Haganir RL (2001) Interaction of the AMPA receptor subunit GluR2/3 with PDZ domains regulates hippocampal long-term depression. *Proc Natl Acad Sci U S A* 98:11725–11730
57. Kim M, Lee HS, Laforet G, McIntyre C, Martin EJ, Chang P, Kim TW, Williams M, Reddy PH, Tagle D, Boyce FM, Won L, Heller A, Aronin N, DiFiglia M (1999) Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition. *J Neurosci* 19:964–973
58. Kim MJ, Futai K, Jo J, Hayashi Y, Cho K, Sheng M (2007) Synaptic accumulation of PSD-95 and synaptic function regulated by phosphorylation of serine-295 of PSD-95. *Neuron* 56:488–502
59. Kirisako T, Ichimura Y, Okada H, Kabeya Y, Mizushima N, Yoshimori T, Ohsumi M, Takao T, Noda T, Ohsumi Y (2000) The reversible modification regulates the membrane-binding state of Apg8/Aut7 essential for autophagy and the cytoplasm to vacuole targeting pathway. *J Cell Biol* 151:263–276
60. Klionsky DJ (2005) The molecular machinery of autophagy: unanswered questions. *J Cell Sci* 118:7–18
61. Klionsky DJ, Cregg JM, Dunn WA Jr, Emr SD, Sakai Y, Sandoval IV, Sibirny A, Subramani S, Thumm M, Veenhuis M, Ohsumi Y (2003) A unified nomenclature for yeast autophagy-related genes. *Dev Cell* 5:539–545
62. Koga H, Martinez-Vicente M, Arias E, Kaushik S, Sulzer D, Cuervo AM (2011) Constitutive upregulation of chaperone-mediated autophagy in Huntington's disease. *J Neurosci* 31:18492–18505
63. Koike M, Shibata M, Tadakoshi M, Gotoh K, Komatsu M, Waguri S, Kawahara N, Kuida K, Nagata S, Kominami E, Tanaka K, Uchiyama Y (2008) Inhibition of autophagy prevents hippocampal pyramidal neuron death after hypoxic-ischemic injury. *Am J Pathol* 172:454–469
64. Komatsu M, Waguri S, Ueno T, Iwata J, Murata S, Tanida I, Ezaki J, Mizushima N, Ohsumi Y, Uchiyama Y, Kominami E, Tanaka K, Chiba T (2005) Impairment of starvation-induced and constitutive autophagy in *Atg7*-deficient mice. *J Cell Biol* 169:425–434
65. Komatsu M, Wang QJ, Holstein GR, Friedrich VL Jr, Iwata J, Kominami E, Chait BT, Tanaka K, Yue Z (2007) Essential role for autophagy protein *Atg7* in the maintenance of axonal homeostasis and the prevention of axonal degeneration. *Proc Natl Acad Sci U S A* 104:14489–14494
66. Kon M, Cuervo AM (2010) Chaperone-mediated autophagy in health and disease. *FEBS Lett* 584:1399–1404
67. Kremer B, Goldberg P, Andrew SE, Theilmann J, Telenius H, Zeisler J, Squitieri F, Lin B, Bassett A, Almqvist E, Bird TD, Hayden MR (1994) A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats. *N Engl J Med* 330:1401–1406
68. Kuma A, Hatano M, Matsui M, Yamamoto A, Nakaya H, Yoshimori T, Ohsumi Y, Tokuhisa T, Mizushima N (2004) The role of autophagy during the early neonatal starvation period. *Nature* 432:1032–1036
69. Lai Y, Hickey RW, Chen Y, Bayir H, Sullivan ML, Chu CT, Kochanek PM, Dixon CE, Jenkins LW, Graham SH, Watkins SC, Clark RS (2008) Autophagy is increased after traumatic brain injury in mice and is partially inhibited by the antioxidant γ -glutamylcysteinyl ethyl ester. *J Cereb Blood Flow Metab* 28:540–550
70. Langlois JA, Rutland-Brown W, Wald MM (2006) The epidemiology and impact of traumatic brain injury: a brief overview. *J Head Trauma Rehabil* 21:375–378
71. Lee H, Noh JY, Oh Y, Kim Y, Chang JW, Chung CW, Lee ST, Kim M, Ryu H, Jung YK (2012) IRE1 plays an essential role in ER stress-mediated aggregation of mutant huntingtin via the inhibition of autophagy flux. *Hum Mol Genet* 21:101–114
72. Lee HK, Kameyama K, Haganir RL, Bear MF (1998) NMDA induces long-term synaptic depression and dephosphorylation of the GluR1 subunit of AMPA receptors in hippocampus. *Neuron* 21:1151–1162

73. Lee HK, Takamiya K, He K, Song L, Haganir RL (2010) Specific roles of AMPA receptor subunit GluR1 (GluA1) phosphorylation sites in regulating synaptic plasticity in the CA1 region of hippocampus. *J Neurophysiol* 103:479–489
74. Lee SH, Liu L, Wang YT, Sheng M (2002) Clathrin adaptor AP2 and NSF interact with overlapping sites of GluR2 and play distinct roles in AMPA receptor trafficking and hippocampal LTD. *Neuron* 36:661–674
75. Lee SH, Simonetta A, Sheng M (2004) Subunit rules governing the sorting of internalized AMPA receptors in hippocampal neurons. *Neuron* 43:221–236
76. Leung LY, VandeVord PJ, Dal Cengio AL, Bir C, Yang KH, King AI (2008) Blast related neurotrauma: a review of cellular injury. *Mol Cell Biomech* 5:155–168
77. Levine B, Klionsky DJ (2004) Development by self-digestion: molecular mechanisms and biological functions of autophagy. *Dev Cell* 6:463–477
78. Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, Yu CE, Jondro PD, Schmidt SD, Wang K, Crowley AC, Fu Y-H, Guenette SY, Galas D, Nemens E, Wijsman EM, Bird TD, Schellenberg GD, Tanzi RE (1995) Candidate gene for the chromosome 1 familial Alzheimer's disease locus. *Science* 269:973–977
79. Li Q, Zhang T, Wang J, Zhang Z, Zhai Y, Yang GY, Sun X (2014) Rapamycin attenuates mitochondrial dysfunction via activation of mitophagy in experimental ischemic stroke. *Biochem Biophys Res Commun* 444:182–188
80. Lighthall JW (1988) Controlled cortical impact: a new experimental brain injury model. *J Neurotrauma* 5:1–15
81. Lin CJ, Chen TH, Yang LY, Shih CM (2014) Resveratrol protects astrocytes against traumatic brain injury through inhibiting apoptotic and autophagic cell death. *Cell Death Dis* 5:e1147. doi:10.1038/cddis.2014.123
82. Liu CL, Chen S, Dietrich D, Hu BR (2008) Changes in autophagy after traumatic brain injury. *J Cereb Blood Flow Metab* 28:674–683
83. Lockshin RA, Zakeri Z (2004) Apoptosis, autophagy, and more. *Int J Biochem Cell Biol* 36:2405–2419
84. Lu W, Shi Y, Jackson AC, Bjorgan K, During MJ, Sprengel R, Seeburg PH, Nicoll RA (2009) Subunit composition of synaptic AMPA receptors revealed by a single-cell genetic approach. *Neuron* 62:254–268
85. Luo CL, Li BX, Li QQ, Chen XP, Sun YX, Bao HJ, Dai DK, Shen YW, Xu HF, Ni H, Wan L, Qin ZH, Tao LY, Zhao ZQ (2011) Autophagy is involved in traumatic brain injury-induced cell death and contributes to functional outcome deficits in mice. *Neuroscience* 184:54–63
86. Lüscher C, Frerking M (2001) Restless AMPA receptors: implications for synaptic transmission and plasticity. *Trends Neurosci* 24:665–670
87. Lv X, Jiang H, Li B, Liang Q, Wang S, Zhao Q, Jiao J (2014) The crucial role of Atg5 in cortical neurogenesis during early brain development. *Sci Rep* 4:6010. doi:10.1038/srep06010
88. Lynch G, Baudry M (1984) The biochemistry of memory: a new and specific hypothesis. *Science* 224:1057–1063
89. Maas AI, Stocchetti N, Bullock R (2008) Moderate and severe traumatic brain injury in adults. *Lancet Neurol* 7:728–741
90. Malenka RC, Nicoll RA (1999) Long-term potentiation—A decade of progress. *Science* 285:1870–1874
91. Man HY, Lin JW, Ju WH, Ahmadian G, Liu L, Becker LE, Sheng M, Wang YT (2000) Regulation of AMPA receptor-mediated synaptic transmission by clathrin-dependent receptor internalization. *Neuron* 25:649–662
92. Manzoni C, Mamais A, Dihanich S, McGoldrick P, Devine MJ, Zerle J, Kara E, Taanman JW, Healy DG, Marti-Masso JF, Schapira AH, Plun-Favreau H, Tooze S, Hardy J, Bandopadhyay R, Lewis PA (2013) Pathogenic Parkinson's disease mutations across the functional domains of LRRK2 alter the autophagic/lysosomal response to starvation. *Biochem Biophys Res Commun* 441:862–866

93. Marmarou A, Foda MA, van den Brink W, Campbell J, Kita H, Demetriadou K (1994) A new model of diffuse brain injury in rats. Part I: pathophysiology and biomechanics. *J Neurosurg* 80:291–300
94. Martinez-Vicente M, Talloczy Z, Wong E, Tang G, Koga H, Kaushik S, de Vries R, Arias E, Harris S, Sulzer D, Cuervo AM (2010) Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease. *Nat Neurosci* 13:567–576
95. Mata IF, Wedemeyer WJ, Farrer MJ, Taylor JP, Gallo KA (2006) LRRK2 in Parkinson's disease: protein domains and functional insights. *Trends Neurosci* 29:286–293
96. Matsuda N, Sato S, Shiba K, Okatsu K, Saisho K, Gautier CA, Sou YS, Saiki S, Kawajiri S, Sato F, Kimura M, Komatsu M, Hattori N, Tanaka K (2010) PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. *J Cell Biol* 189:211–221
97. McCoy MK, Cookson MR (2011) DJ-1 regulation of mitochondrial function and autophagy through oxidative stress. *Autophagy* 7:531–532
98. Mercer CA, Kaliappan A, Dennis PB (2009) A novel, human Atg13 binding protein, Atg101, interacts with ULK1 and is essential for macroautophagy. *Autophagy* 5:649–662
99. Mijaljica D, Prescott M, Devenish RJ (2011) Microautophagy in mammalian cells Revisiting a 40-year-old conundrum. *Autophagy* 7:673–682
100. Ming GL, Song H (2011) Adult neurogenesis in the mammalian brain: significant answers and significant questions. *Neuron* 70:687–702
101. Mizushima N (2005) The pleiotropic role of autophagy: from protein metabolism to bactericide. *Cell Death Differ* 12:1535–1541
102. Mizushima N, Klionsky DJ (2007) Protein turnover via autophagy: implications for metabolism. *Annu Rev Nutr* 27:19–40
103. Mizushima N, Kuma A, Kobayashi Y, Yamamoto A, Matsubae M, Takao T, Natsume T, Ohsumi Y, Yoshimori T (2003) Mouse Apg16L, a novel WD-repeat protein, targets to the autophagic isolation membrane with the Apg12–Apg5 conjugate. *J Cell Sci* 116:1679–1688
104. Mizushima N, Levine B (2010) Autophagy in mammalian development and differentiation. *Nat Cell Biol* 12:823–830
105. Mizushima N, Sugita H, Yoshimori T, Ohsumi Y (1998) A new protein conjugation system in human. The counterpart of the yeast Apg12p conjugation system essential for autophagy. *J Biol Chem* 273:33889–33892
106. Mizushima N, Yamamoto A, Matsui M, Yoshimori T, Ohsumi Y (2004) In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. *Mol Biol Cell* 15:1101–1111
107. Mizushima N, Yoshimori T, Levine B (2010) Methods in mammalian autophagy research. *Cell* 140:313–326
108. Molinari M, Viscomi MT, Leggio MG (2013) Hemicerebellectomy. In: Manto M, Schmahmann JD, Rossi F, Gruol DL, Koibuchi N (eds) *Handbook of the cerebellum and cerebellar disorders*. Springer, Dordrecht, pp 1579–1594
109. Moore DJ, West AB, Dawson VL, Dawson TM (2005) Molecular pathophysiology of Parkinson's disease. *Annu Rev Neurosci* 28:57–87
110. Nakatogawa H, Suzuki K, Kamada Y, Ohsumi Y (2009) Dynamics and diversity in autophagy mechanisms: lessons from yeast. *Nat Rev Mol Cell Biol* 10:458–467
111. Narendra DP, Jin SM, Tanaka A, Suen DF, Gautier CA, Shen J, Cookson MR, Youle RJ (2010) PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. *PLoS Biol* 8:e1000298. doi:10.1371/journal.pbio.1000298
112. Nixon RA, Wegiel J, Kumar A, Yu WH, Peterhoff C, Cataldo A, Cuervo AM (2005) Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. *J Neuropathol Exp Neurol* 64:113–122
113. Osten P, Khatri L, Perez JL, Köhr G, Giese G, Daly C, Schulz TW, Wensky A, Lee LM, Ziff EB (2000) Mutagenesis reveals a role for ABP/GRIP binding to GluR2 in synaptic surface accumulation of the AMPA receptor. *Neuron* 27:313–325

114. Park M, Penick EC, Edwards JG, Kauer JA, Ehlers MD (2004) Recycling endosomes supply AMPA receptors for LTP. *Science* 305:1972–1975
115. Parzych KR, Kliionsky DJ (2014) An overview of autophagy: morphology, mechanism, and regulation. *Antioxid Redox Signal* 20:460–473
116. Passafaro M, Piech V, Sheng M (2001) Subunit-specific temporal and spatial patterns of AMPA receptor exocytosis in hippocampal neurons. *Nat Neurosci* 4:917–926
117. Perez JL, Khatri L, Chang C, Srivastava S, Osten P, Ziff EB (2001) PICK1 targets activated protein kinase C alpha to AMPA receptor clusters in spines of hippocampal neurons and reduces surface levels of the AMPA-type glutamate receptor subunit 2. *J Neurosci* 21:5417–5428
118. Petersén A, Larsen KE, Behr GG, Romero N, Przedborski S, Brundin P, Sulzer D (2001) Expanded CAG repeats in exon 1 of the Huntington's disease gene stimulate dopamine-mediated striatal neuron autophagy and degeneration. *Hum Mol Genet* 10:1243–1254
119. Pickford F, Masliah E, Britschgi M, Lucin K, Narasimhan R, Jaeger PA, Small S, Spencer B, Rockenstein E, Levine B, Wyss-Coray T (2008) The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. *J Clin Invest* 118:2190–2199
120. Popa C, Popa F, Grigorean VT, Onose G, Sandu AM, Popescu M, Burnei G, Strambu V, Sinescu C (2010) Vascular dysfunctions following spinal cord injury. *J Med Life* 3:275–285
121. Puyal J, Vaslin A, Mottier V, Clarke PG (2009) Postischemic treatment of neonatal cerebral ischemia should target autophagy. *Ann Neurol* 66:378–389
122. Qi L, Zhang XD, Wu JC, Lin F, Wang J, DiFiglia M, Qin ZH (2012) The role of chaperone-mediated autophagy in huntingtin degradation. *PLoS One* 7:e46834. doi:[10.1371/journal.pone.0046834](https://doi.org/10.1371/journal.pone.0046834)
123. Qu X, Zou Z, Sun Q, Luby-Phelps K, Cheng P, Hogan RN, Gilpin C, Levine B (2007) Autophagy gene-dependent clearance of apoptotic cells during embryonic development. *Cell* 128:931–946
124. Ramesh Babu J, Lamar Seibenhener M, Peng J, Strom AL, Kempainen R, Cox N, Zhu H, Wooten MC, Diaz-Meco MT, Moscat J, Wooten MW (2008) Genetic inactivation of p62 leads to accumulation of hyperphosphorylated tau and neurodegeneration. *J Neurochem* 106:107–120
125. Ravikumar B, Duden R, Rubinsztein DC (2002) Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. *Hum Mol Genet* 11:1107–1117
126. Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG, Scaravilli F, Easton DF, Duden R, O'Kane CJ, Rubinsztein DC (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. *Nat Genet* 36:585–595
127. Ribas VT, Schnepf B, Challagundla M, Koch JC, Bähr M, Lingor P (2014) Early and sustained activation of autophagy in degenerating axons after spinal cord injury. *Brain Pathol* 25:157–170
128. Rowland AM, Richmond JE, Olsen JG, Hall DH, Bamber BA (2006) Presynaptic terminals independently regulate synaptic clustering and autophagy of GABAA receptors in *Caenorhabditis elegans*. *J Neurosci* 26:1711–1720
129. Rubinsztein DC, Leggo J, Coles R, Almqvist E, Biancalana V, Cassiman JJ, Chotai K, Connarty M, Craufurd D, Curtis A, Curtis D, Davidson MJ, Differ AM, Dode C, Dodge A, Frontali M, Ranen NG, Stine OC, Sherr M, Abbott MH, Franz ML, Graham CA, Harper PS, Hedreen JC, Jackson A, Kaplan JC, Losekoot M, MacMillan JC, Morrison P, Trottier Y, Novelletto A, Simpson SA, Theilmann J, Whittaker JL, Folstein SE, Ross CA, Hayden MR (1996) Phenotypic characterization of individuals with 30–40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36–39 repeats. *Am J Hum Genet* 59:16–22

130. Saha S, Liu-Yesucevitz L, Wolozin B (2014) Regulation of autophagy by LRRK2 in *Caenorhabditis elegans*. *Neurodegener Dis* 13:110–113
131. Saitoh T, Fujita N, Hayashi T, Takahara K, Satoh T, Lee H, Matsunaga K, Kageyama S, Omori H, Noda T, Yamamoto N, Kawai T, Ishii K, Takeuchi O, Yoshimori T, Akira S (2009) Atg9a controls dsDNA-driven dynamic translocation of STING and the innate immune response. *Proc Natl Acad Sci U S A* 106:20842–20846
132. Saitoh T, Fujita N, Jang MH, Uematsu S, Yang BG, Satoh T, Omori H, Noda T, Yamamoto N, Komatsu M, Tanaka K, Kawai T, Tsujimura T, Takeuchi O, Yoshimori T, Akira S (2008) Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1b production. *Nature* 456:264–268
133. Sánchez-Pérez AM, Claramonte-Clausell B, Sánchez-Andrés JV, Herrero MT (2012) Parkinson's disease and autophagy. *Parkinsons Dis* 2012:429524. doi:[10.1155/2012/429524](https://doi.org/10.1155/2012/429524)
134. Santos RX, Correia SC, Wang X, Perry G, Smith MA, Moreira PI, Zhu X (2010) Alzheimer's disease: diverse aspects of mitochondrial malfunctioning. *Int J Clin Exp Pathol* 3:570–581
135. Sapp E, Schwarz C, Chase K, Bhide PG, Young AB, Penney J, Vonsattel JP, Aronin N, DiFiglia M (1997) Huntingtin localization in brains of normal and Huntington's disease patients. *Ann Neurol* 42:604–612
136. Sarkar S (2013) Regulation of autophagy by mTOR-dependent and mTOR-independent pathways: autophagy dysfunction in neurodegenerative diseases and therapeutic application of autophagy enhancers. *Biochem Soc Trans* 41:1103–1130
137. Sarkar S, Perlstein EO, Imarisio S, Pineau S, Cordenier A, Maglathlin RL, Webster JA, Lewis TA, O'Kane CJ, Schreiber SL, Rubinsztein DC (2007) Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. *Nat Chem Biol* 3:331–338
138. Selkoe DJ (2000) Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. *Ann N Y Acad Sci* 924:17–25
139. Shaid S, Brandts CH, Serve H, Dikic I (2013) Ubiquitination and selective autophagy. *Cell Death Differ* 20:21–30
140. Shehata M, Matsumura H, Okubo-Suzuki R, Ohkawa N, Inokuchi K (2012) Neuronal stimulation induces autophagy in hippocampal neurons that is involved in AMPA receptor degradation after chemical long-term depression. *J Neurosci* 32:10413–10422
141. Sheng M, Lee SH (2001) AMPA receptor trafficking and the control of synaptic transmission. *Cell* 105:825–828
142. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, Tsuda T, Mar L, Foncin JF, Bruni AC, Montesi MP, Sorbi S, Rainero I, Pinessi L, Nee L, Chumakov I, Pollen D, Brookes A, Sanseau P, Polinsky RJ, Wasco W, Da Silva HA, Haines JL, Pericak-Vance MA, Tanzi RE, Roses AD, Fraser PE, Rommens JM, St George-Hyslop PH (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. *Nature* 375:754–760
143. Shi S, Hayashi Y, Esteban JA, Malinow R (2001) Subunit-specific rules governing AMPA receptor trafficking to synapses in hippocampal pyramidal neurons. *Cell* 105:331–343
144. Shi S, Hayashi Y, Petralia RS, Zaman SH, Wenthold RJ, Svoboda K, Malinow R (1999) Rapid spine delivery and redistribution of AMPA receptors after synaptic NMDA receptor activation. *Science* 284:1811–1815
145. Sou YS, Waguri S, Iwata J, Ueno T, Fujimura T, Hara T, Sawada N, Yamada A, Mizushima N, Uchiyama Y, Kominami E, Tanaka K, Komatsu M (2008) The Atg8 conjugation system is indispensable for proper development of autophagic isolation membranes in mice. *Mol Biol Cell* 19:4762–4775
146. Suzuki K, Kubota Y, Sekito T, Ohsumi Y (2007) Hierarchy of Atg proteins in pre-autophagosomal structure organization. *Genes Cells* 12:209–218
147. Tang G, Gudsnek K, Kuo SH, Cotrina ML, Rosoklija G, Sosunov A, Sonders MS, Kanter E, Castagna C, Yamamoto A, Yue Z, Arancio O, Peterson BS, Champagne F, Dwork AJ,

- Goldman J, Sulzer D (2014) Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits. *Neuron* 83:1131–1143
148. Tanida I, Tanida-Miyake E, Ueno T, Kominami E (2001) The human homolog of *Saccharomyces cerevisiae* Apg7p is a protein-activating enzyme for multiple substrates including human Apg12p, GATE-16, GABARAP, and MAP-LC3. *J Biol Chem* 276:1701–1706
149. Tanzi RE, Gussella JF, Walkins PC, Bruns GA, St. George-Hyslop P, Van Keuren ML, Patterson D, Pagan S, Kurnit DM, Neve RL (1987) Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. *Science* 235:880–884
150. Tatsuta T, Langer T (2008) Quality control of mitochondria: protection against neurodegeneration and ageing. *EMBO J* 27:306–314
151. Tomoda T, Bhatt RS, Kuroyanagi H, Shirasawa T, Hatten ME (1999) A mouse serine/threonine kinase homologous to *C. elegans* UNC51 functions in parallel fiber formation of cerebellar granule neurons. *Neuron* 24:833–846
152. Tomoda T, Kim JH, Zhan C, Hatten ME (2004) Role of Unc51.1 and its binding partners in CNS axon outgrowth. *Genes Dev* 18:541–558
153. Toyoda H, Wu LJ, Zhao MG, Xu H, Jia Z, Zhuo M (2007) Long-term depression requires postsynaptic AMPA GluR2 receptor in adult mouse cingulate cortex. *J Cell Physiol* 211:336–343
154. Velier J, Kim M, Schwarz C, Kim TW, Sapp E, Chase K, Aronin N, DiFiglia M (1998) Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways. *Exp Neurol* 152:34–40
155. Viscomi MT, D'Amelio M, Cavallucci V, Latini L, Bisicchia E, Nazio F, Fanelli F, Maccarrone M, Moreno S, Cecconi F, Molinari M (2012) Stimulation of autophagy by rapamycin protects neurons from remote degeneration after acute focal brain damage. *Autophagy* 8:222–235
156. Viscomi MT, Molinari M (2014) Remote neurodegeneration: multiple actors for one play. *Mol Neurobiol* 50:368–389
157. Walker FO (2007) Huntington's disease. *Lancet* 369:218–228
158. Wang T, Zhang L, Zhang M, Bao H, Liu W, Wang Y, Wang L, Dai D, Chang P, Dong W, Chen X, Tao L (2013) [Gly14]-Humanin reduces histopathology and improves functional outcome after traumatic brain injury in mice. *Neuroscience* 231:70–81
159. Wang X, Su B, Zheng L, Perry G, Smith MA, Zhu X (2009) The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease. *J Neurochem* 109:153–159
160. Wang Y, Martinez-Vicente M, Krüger U, Kaushik S, Wong E, Mandelkow EM, Cuervo AM, Mandelkow E (2009) Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing. *Hum Mol Genet* 18:4153–4170
161. Wang YQ, Wang L, Zhang MY, Wang T, Bao HJ, Liu WL, Dai DK, Zhang L, Chang P, Dong WW, Chen XP, Tao LY (2012) Necrostatin-1 suppresses autophagy and apoptosis in mice traumatic brain injury model. *Neurochem Res* 37:1849–1858
162. Webb AA, Ngan S, Fowler JD (2010) Spinal cord injury I: a synopsis of the basic science. *Can Vet J* 51:485–492
163. Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC (2003) α -Synuclein is degraded by both autophagy and the proteasome. *J Biol Chem* 278:25009–25013
164. Wen YD, Sheng R, Zhang LS, Han R, Zhang X, Zhang XD, Han F, Fukunaga K, Qin ZH (2008) Neuronal injury in rat model of permanent focal cerebral ischemia is associated with activation of autophagic and lysosomal pathways. *Autophagy* 4:762–769
165. Wenthold RJ, Petralia RS, Blahos J II, Niedzielski AS (1996) Evidence for multiple AMPA receptor complexes in hippocampal CA1/CA2 neurons. *J Neurosci* 16:1982–1989
166. Xie Z, Klionsky DJ (2007) Autophagosome formation: core machinery and adaptations. *Nat Cell Biol* 9:1102–1109

167. Xing S, Zhang Y, Li J, Zhang J, Li Y, Dang C, Li C, Fan Y, Yu J, Pei Z, Zeng J (2012) Beclin 1 knockdown inhibits autophagic activation and prevents the secondary neurodegenerative damage in the ipsilateral thalamus following focal cerebral infarction. *Autophagy* 8:63–76
168. Xiong Y, Mahmood A, Chopp M (2013) Animal models of traumatic brain injury. *Nat Rev Neurosci* 14:128–142
169. Yamamoto H, Kakuta S, Watanabe TM, Kitamura A, Sekito T, Kondo-Kakuta C, Ichikawa R, Kinjo M, Ohsumi Y (2012) Atg9 vesicles are an important membrane source during early steps of autophagosome formation. *J Cell Biol* 198:219–233
170. Yang DS, Stavrides P, Mohan PS, Kaushik S, Kumar A, Ohno M, Schmidt SD, Wesson D, Bandyopadhyay U, Jiang Y, Pawlik M, Peterhoff CM, Yang AJ, Wilson DA, St George-Hyslop P, Westaway D, Mathews PM, Levy E, Cuervo AM, Nixon RA (2011) Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits. *Brain* 134:258–277
171. Yazdankhah M, Farioli-Vecchioli S, Tonchev AB, Stoykova A, Cecconi F (2014) The autophagy regulators Ambra1 and Beclin 1 are required for adult neurogenesis in the brain subventricular zone. *Cell Death Dis* 5:e1403. doi:10.1038/cddis.2014.358
172. Yu WH, Cuervo AM, Kumar A, Peterhoff CM, Schmidt SD, Lee JH, Mohan PS, Mercken M, Farmery MR, Tjernberg LO, Jiang Y, Duff K, Uchiyama Y, Näslund J, Mathews PM, Cataldo AM, Nixon RA (2005) Macroautophagy – a novel beta-amyloid peptide-generating pathway activated in Alzheimer's disease. *J Cell Biol* 171:87–98
173. Yu WH, Kumar A, Peterhoff C, Shapiro Kulnane L, Uchiyama Y, Lamb BT, Cuervo AM, Nixon RA (2004) Autophagic vacuoles are enriched in amyloid precursor protein-secretase activities: implications for beta-amyloid peptide over-production and localization in Alzheimer's disease. *Int J Biochem Cell Biol* 36:2531–2540
174. Yue Z, Jin S, Yang C, Levine AJ, Heintz N (2003) Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. *Proc Natl Acad Sci U S A* 100:15077–15082
175. Zhang H, Duan C, Yang H (2015) Defective autophagy in Parkinson's disease: lessons from genetics. *Mol Neurobiol* 51:89–104
176. Zhang M, Shan H, Chang P, Wang T, Dong W, Chen X, Tao L (2014) Hydrogen sulfide offers neuroprotection on traumatic brain injury in parallel with reduced apoptosis and autophagy in mice. *PLoS One* 9:e87241. doi:10.1371/journal.pone.0087241
177. Zhang X, Yan H, Yuan Y, Gao J, Shen Z, Cheng Y, Shen Y, Wang RR, Wang X, Hu WW, Wang G, Chen Z (2013) Cerebral ischemia-reperfusion-induced autophagy protects against neuronal injury by mitochondrial clearance. *Autophagy* 9:1321–1333
178. Zhang YB, Li SX, Chen XP, Yang L, Zhang YG, Liu R, Tao LY (2008) Autophagy is activated and might protect neurons from degeneration after traumatic brain injury. *Neurosci Bull* 24:143–149
179. Zhao T, Severijnen LA, van der Weiden M, Zheng PP, Oostra BA, Hukema RK, Willemsen R, Kros JM, Bonifati V (2013) FBXO7 immunoreactivity in alpha-synuclein-containing inclusions in Parkinson disease and multiple system atrophy. *J Neuropathol Exp Neurol* 72:482–488
180. Zhou X, Babu JR, da Silva S, Shu Q, Graef IA, Oliver T, Tomoda T, Tani T, Wooten MW, Wang F (2007) Unc-51-like kinase 1/2-mediated endocytic processes regulate filopodia extension and branching of sensory axons. *Proc Natl Acad Sci U S A* 104:5842–5847
181. Zhou Z, Hu J, Passafaro M, Xie W, Jia Z (2011) GluA2 (GluR2) regulates metabotropic glutamate receptor-dependent long-term depression through N-cadherin-dependent and cofilin-mediated actin reorganization. *J Neurosci* 31:819–833